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BACKGROUND: Numerous chemicals are capable of disrupting androgen production, but the possibility that they might act together to produce effects
greater than those of the most effective component in the mixture has not been studied directly in human tissues. Suppression of androgen synthesis
in fetal life has been associated with testis maldescent, malformations of the genitalia at birth, and poor semen quality later in life.
OBJECTIVES: Our aim was to investigate whether chemicals can act together to disrupt androgen production in human fetal testis explants and to eval-
uate the importance of mixture effects when characterizing the hazard of individual chemicals.
METHODS: We used an organotypic culture system of human fetal testes explants called FEtal Gonad Assay (FEGA) with tissue obtained at 10 and
12 gestational wk (GW 10–12), to screen 27 chemicals individually for their possible anti-androgenic effect. Based on the results of the screen, we
selected 11 compounds and tested them as mixtures.
RESULTS:We evaluated mixtures composed of four and eight antiandrogens that contained the pharmaceuticals ketoconazole and theophylline and
several previously untested chemicals, such as the pesticides imazalil and propiconazole. Mixtures of antiandrogens can suppress testosterone syn-
thesis in human fetal testicular explants to an extent greater than that seen with individual chemicals. This revealed itself as a shift towards lower
doses in the dose–response curves of individual antiandrogens that became more pronounced as the number of components increased from four to
eight.
CONCLUSIONS: Our results with the FEGA provide the foundations of a predictive human mixture risk assessment approach for anti-androgenic expo-
sures in fetal life. https://doi.org/10.1289/EHP1014
Introduction
In chemical hazard characterizations for pesticides, biocides, and
other potentially toxic chemicals, single substances are tested in
relevant animal studies with the aim of estimating exposures that
are without apparent effects. These estimates form the basis for
deriving human reference doses commonly regarded as safe lev-
els of exposure. Normally, this exercise is conducted by consider-
ing one chemical at a time, but this single chemical approach
does not account for the possibility that simultaneous exposures
to other chemicals may also contribute to the toxicity under con-
sideration. As a consequence, single chemical exposures judged
to be safe in isolation may in reality pose significant risks, if there
is co-exposure to mixtures of substances with similar toxicities.
However, the impact of not considering such co-exposures on
risk estimates as well as the relevance of co-exposures on the
safe use of drugs remains poorly defined.
Potentially higher risks of mixtures need to be taken into
account, particularly when the health effects are irreversible, such
as those arising from disrupting the action of hormones during
key stages of development. Here we investigate the combined
effects of chemicals that interfere with androgen action in
human testicular tissue. During the first trimester of pregnancy,
fetal androgens play a key role in the development and growth
of the male reproductive tract, specifically by regulating testicu-
lar descent, penile development, and organization of seminifer-
ous tubules (Huhtaniemi 1994). Animal toxicology studies and
human epidemiology studies have shown that disruption of
androgen action at this time can have irreversible consequences
at birth, including testis maldescent (cryptorchidism) and penile
malformations where the urethral opening is placed on the
underside of the penis (hypospadias). Analysis of secular trends
in humans have revealed increasing prevalence of these disor-
ders in some industrialized countries; furthermore, cryptorchid-
ism and hypospadias are increased risk factors for testicular
cancer (Cook et al. 2010; Serrano et al. 2013; Skakkebaek et al.
2016).
Numerous chemicals have been identified as antiandrogens in
experimental animals and cell-based systems and have been
shown to induce androgen insufficiency by several modes of
action: suppressing androgen synthesis, blocking the androgen re-
ceptor, or altering the signaling of local mediators such as prosta-
glandins. Prominent examples of anti-androgenic chemicals include
certain phthalates used as plasticizers, pesticides, and mild analge-
sics (Albert and Jégou 2014; Ben Maamar et al. 2017; Kristensen
et al. 2016; Mazaud-Guittot et al. 2013; Orton et al. 2011; van den
Driescheet al. 2015a).
The combined effects of anti-androgenic chemicals have been
assessed in cell-based assays that capture responses close to the
molecular events of androgen receptor activation or steroid syn-
thesis (Ermler et al. 2011; Orton et al. 2014; Taxvig et al. 2013)
and in animal studies by investigating endpoints indicative of
disruption of androgen action at the physiological level (Christiansen
et al. 2012; Hass et al. 2007; Howdeshell et al. 2015). This body of
Address correspondence to B. Jégou, EHESP, IRSET-UMR Inserm 1085, 9
Ave. du professeur Léon Bernard, F-35000 Rennes, France. Telephone:
33.2.23.23.61.25. Email: bernard.jegou@ehesp.fr
Supplemental Material is available online (https://doi.org/10.1289/
EHP1014).
The authors declare they have no actual or potential competing financial
interest and that funders had no role in the study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Received 25 August 2016; Revised 2 March 2017; Accepted 20 March
2017; Published 4 August 2017.
Note to readers with disabilities: EHP strives to ensure that all journal
content is accessible to all readers. However, some figures and Supplemental
Material published in EHP articles may not conform to 508 standards due to
the complexity of the information being presented. If you need assistance
accessing journal content, please contact ehponline@niehs.nih.gov. Our staff
will work with you to assess and meet your accessibility needs within
3 working days.
Environmental Health Perspectives 087004-1
A Section 508–conformant HTML version of this article
is available at https://doi.org/10.1289/EHP1014.Research
work demonstrated that chemicals with greatly varying structural
features and modes of action can act together to produce anti-
androgenic effects such that the toxicity of the mixture is greater
than that of themost effective single component.
However, it is difficult to apply this evidence directly in
human risk assessment. Mixture studies with cell-based assays
can provide clues as to the possibility of combination effects at
the molecular level of hormone signaling, but do not necessarily
predict how such effects will play out in vivo at concentrations to
which humans may be exposed. Cell-based assays help inform
the design of animal studies on the consequences of androgen
insufficiency in vivo, but animal studies do not necessarily reflect
the human situation. For example, the androgen synthesis-
suppressing effects of phthalates and bisphenol A (BPA) in the
rat might not be predictive of responses in fetal human tissues
(Ben Maamar et al. 2015; van den Driesche et al. 2015b).
Furthermore, human health studies cannot provide direct answers
about causation, whether for single chemicals or mixtures of
chemicals (Braun et al. 2016).
Here we use a novel alternative approach that exposes iso-
lated human fetal testicular tissue to specific mixtures of chemi-
cals in vitro, the FEtal Gonad Assay (FEGA) (Ben Maamar et al.
2015, 2017; Mazaud-Guittot et al. 2013). FEGA maintains the
complexity of human fetal testicular tissues during the time of
the culture, including its ability to synthesize testosterone.
Therefore, it offers the possibility of investigating chemical
effects on testosterone synthesis in human fetal testis tissue
obtained toward the end of the first trimester of pregnancy, a
time when testosterone plays key roles in human reproductive
tract development. Furthermore, we applied a predictive model-
ing approach to mixtures that reduces the need for testing every
conceivable combination of chemicals one by one.
Methods
Chemicals
We selected the following chemicals for our studies: bisphenol A
(BPA, 239658, CAS No. 80-05-7), ketoconazole (K1003, CAS
No. 65277-42-1), bisphenol S (BPS, 103039, CAS No. 80-09-1),
clomiphene (C6272, CAS No. 50-41-9, analytical standard), the-
ophylline (T1633, CAS No. 58-55-9), prochloraz (45631, CAS
No. 67747-09-5, analytical standard), imazalil (32007, CAS No.
35554-44-0, analytical standard), bitertanol (45349, CAS No.
55179-31-2, analytical standard), propiconazole (45642, CAS
No. 60207-90-1, analytical standard), valproic acid (P4543, CAS
No. 99-66-1), and chlordecone (SC-394278, CAS No. 143-50-0,
Santa Cruz, Dallas, TX, USA). All chemicals were obtained from
Sigma-Aldrich, except chlordecone.
Collection of Human Samples
First trimester human fetal testes were obtained from pregnant
women after legally induced abortions in collaboration with the
University Hospital of Rennes (France); all women received in-
formation and gave written consent in accordance with the
French national guidelines (Agence de la Biomédecine, authori-
zation PFS09–011). We obtained approval from the local ethics
committee of Rennes (advice # 11–48). Women did not receive
any financial compensation for donating tissue. The testes were
recovered from the aspiration product by examination with a
binocular microscope (Olympus SZX7) and immediately placed
in cold phosphate buffered saline (PBS). Testes were selected
only from GW 10–12 because, in our experience, they are well
suited to test multiple concentrations of chemicals in the same
testis (Ben Maamar et al. 2015, 2017; Mazaud-Guittot et al.
2013). Also, this is a likely pertinent window of sensitivity for
the action of fetal testosterone in directing male reproductive
tract development in humans (Welsh et al. 2008).
Fetal Testis Culture
The fetal testes were cultured as previously described (Ben
Maamar et al. 2015). Briefly, testes were cut into approximately
1-mm3 pieces and each explant was cultured separately. At least
two explants per fetus were cultured in control conditions.
Explants were placed onto culture inserts (0:4-lmpores) in 24-
well companion plates. Each well was filled with 350 lL phenol
red–free medium 199 (21157-029, Invitrogen Life Technologies,
Saint Aubin, France) supplemented with 50 lg=mL gentamicin
(G1272, Sigma-Aldrich, Saint-Quentin, France) and 2:5 lg=mL
Fungizone (A2942, Sigma-Aldrich). Human chorionic gonado-
trophin (CG5, Sigma-Aldrich) was added to a final concentration
of 0:1 IU=mL, which was found in our previous experiments to
sustain steroidogenic responsiveness and the integrity of the tis-
sue (Hallmark et al. 2007; Mazaud-Guittot et al. 2013). Cultures
were incubated at 37°C for 96 h under a humidified atmosphere
of 95% air and 5% CO2. The medium was changed every 24 h
and immediately snap-frozen on dry ice and stored at −80C.
The first 24 h of culture were conducted without addition of test
chemicals or their mixtures. This served as a baseline for hor-
mone production, allowing normalization of explant secretory
capacity before the addition of chemicals alone or as mixtures.
Dimethylsulfoxyde (DMSO, 34943, CAS No. 67-68-5, Sigma-
Aldrich) was used to dilute chemicals [except for the BPA stock
solution, which was diluted in ethanol (UN1170, CAS No. 64-
17-5, TechniSolv, Fontenay-sous-bois, France)] and as a solvent
control to a final concentration of 0.1%. The final concentration
of ethanol was <0:001% (v:v).
Immunostaining and Cytotoxicity
To ensure that inherent toxicity of our tested chemicals and their
mixtures did not induce a downturn in testosterone synthesis,
thereby confounding any genuine anti-androgenic effects, we
assessed the functional integrity of the testosterone-producing
Leydig cell population by immunolabeling of cytochrome P450
(CYP11A1), a key enzyme of the androgen biosynthesis path-
way. We also monitored cell apoptosis by immunolabeling of
cleaved caspase 3. After fixation in paraformaldehyde or Bouin
solution and paraffin embedding, the randomly collected exposed
explants were cut, mounted into slides, and labeled with either a
rabbit anti-cytochrome P450, family 11, subfamily A, polypep-
tide 1 (CYP11A1) antibody (1/200; HPA016436, Sigma-Aldrich)
or a rabbit anticleaved capsase-3 antibody 1/200; 9661S (Cell
Signaling Technology), as described by Ben Maamar et al.
2015). Cleaved caspase-3 immunostaining required a step of anti-
gen retrieval performed by incubation in preheated Tris-
EDTAbuffer 10=1mM (pH 9.0) at 80C for 40 min and cooled at
room temperature (Ben Maamar et al. 2015). All the microscopic
observations were made at low and high magnifications, and rep-
resentative photos were taken at 40× magnification. Taken alone
or in combination, both the testicular histopathology, the Leydig
cell labeling and the cleaved caspase-3 positive cells staining pro-
vided a qualitative overall assessment of the integrity of the
explant for each chemical at any concentration.
Testosterone Assay
The testosterone levels measured in the FEGA are influenced by
maternal factors, the intrinsic properties of the fetal testes, their
age, the size of the explants, and the precise culture conditions.
These factors inevitably introduce considerable variations of the
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measured hormone levels. Out of concerns that this variability
might complicate dose–response analyses and create serious diffi-
culties during the interpretation of mixture experiments, we took
steps to improve the reproducibility of assay responses by work-
ing with a tightly controlled age range of fetal testes (GW 10–
12). We also obtained several explants per testes, which enabled
us to test multiple concentrations of a chemical with the same
material. The size of the explants was rigorously controlled
and a normalization procedure allowed us to increase statisti-
cal power by pooling the results from multiple experimental
sessions.
Testosterone levels from each testis explant were measured at
the beginning of the experiment [day 0 (D0), that is, after 24 h of
culture] and after 72 h in culture media (D3). Measurements at
D0 were used as reference baseline for the normalization of hor-
mone production per testis. This procedure was adhered to for all
treated and untreated samples, and each sample was assayed
in duplicate in a radioimmunoassay (RIA) according to the kit
manufacturer’s instructions [testosterone direct RIA; Beckman
Coulter, Villepinte, France; intra-assay coefficient of variation
(CV) of 5.6% and interassay (CV) of 15%].
Experimental Testing
Range-finding experiments were performed for each compound
to identify nontoxic concentration ranges. Definite studies were
then conducted to obtain data for the entire effect range of testos-
terone production, with individual compounds and mixtures run
on explants from 3 to 12 different testis. At last three different
concentrations were tested. All experiments were run with a fixed
DMSO concentration of 0.1% among the tested doses range. A
positive control of 10−5M ketoconazole was used in each study
(Mazaud-Guittot et al. 2013).
Design of Mixture Experiments
Multi-component mixtures were evaluated by comparing their
experimentally observed responses with those predicted by a
dose-addition model (DA) (Loewe and Muischnek 1926). This
pharmacological model uses the dose–response information from
all individual compounds that are present in the mixture. We
used a stepwise approach: a) Compounds were tested individu-
ally to provide sufficient data for the statistical dose–response
regression analysis; b) pooled data from each compound were
used to establish a statistical best-fitting regression model; c)
equi-potent mixtures were designed according to the “fixed mix-
ture ratio design” (Faust et al. 2001), where mixture ratios were
chosen in line with the potencies of the mixture components and
additivity expectations were calculated; and d) mixtures were
tested under exactly the same experimental conditions as the indi-
vidual compounds and their observed effects were compared to
the predicted responses. For details of the composition of the
mixtures, see Table 1.
Mixture effects were predicted according to the model of DA












where ECx1 to n are the effect concentrations of the single com-
pounds in the mixture that each on their own produces the same
quantitative effect x as the mixture, and p1 to n defined as the prev-
alence of a mixture component in the mixture, that is, the ratio of
its concentration to the total mixture concentration (see mixture
ratio in Table 1). The statistical uncertainty for the predicted mix-
ture effects and effect concentration was estimated using the boot-
strap method (Efron and Tibshirani 1994) and expressed as 95%
confidence limits for the predicted mean estimate. Differences
between predicted and observed effect concentrations were con-
sidered as statistically significant when the 95% confidence belts
of the prediction did not overlap with those of the experimentally
observed mixture effects.
Mixture Testing
Four different mixtures were investigated. They were composed
of ketoconazole, BPA, valproic acid, and clomiphene (mixture I);
ketoconazole, BPA, valproic acid, and theophylline (mixture II);
ketoconazole, BPA, valproic acid, clomiphene, theophylline,
chlordecone, BPS, and imazalil (mixture III); and bitertanol,
BPA, prochloraz, propiconazole, theophylline, chlordecone, BPS,
and imazalil (mixture IV). The mixture concentrations to be
tested were chosen according to the DA expectations, by estab-
lishing a geometric sequence of concentrations bounded by the
lowest concentration predicted to inhibit the testosterone produc-
tion only minimally and the highest concentration predicted to
stop the production altogether. All mixture solutions were pre-
pared in DMSO for a final concentration of DMSO equal to 0.1%
in each cultured well.
Data Normalization during Dose–Response Analysis
The baseline testosterone production depends on various factors,
such as age of the fetus, pregnancy circumstances, and lifestyle
pattern of the mothers, and because these factors are not con-
trolled (or are unknown), they might lead to considerable vari-
ability between the individual control measurements. This
Table 1.Model parameters for all tested single compounds and composition of the tested mixtures.
Chemical





2 EC50 (M) Toxicity (M) Mix I Mix II Mix III Mix IV
Ketoconazole Weibull −15:49 −2:52 9:97× 10−7 10−5 0.20 0.20 0.025
BPA Weibull −10:80 −2:00 6:07× 10−6 >10−5 0.45 0.45 0.053 0.057
Valproic acid Weibull −8:73 −1:57 4:71× 10−6 >10−5 0.16 0.30 0.021
Clomiphene Logit −12:11 −2:31 5:72× 10−6 >10−5 0.19 0.026
Theophylline Logit −1:59 −0:37 5:04× 10−5 10−5 0.05 0.002 2:21× 10−5
BPS Weibull −12:10 −2:54 1:72× 10−5 10−4 0.355 0.302
Chlordecone Logit −14:90 −3:04 1:66× 10−5 10−4 0.243 0.277
Imazalil Logit −13:80 −2:74 9:19× 10−6 10−4 0.275 0.337
Bitertanol Logit −7:62 −1:56 1:30× 10−5 10−5 0.003
Prochloraz Logit −14:70 −2:21 2:23× 10−7 10−5 0.001





2 are estimates of the unknown model parameters h1 and h2. EC50 represents the mean molar concentration (M, mol=L) of a chemical that provokes a 50% suppression
of testosterone levels in the FEGA. Mix, mixture.
aExpressed as the fraction of the dose of each single chemical in the total mixture dose.
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suggests that whenever possible, individual testosterone measure-
ments should be referenced only to the same fetus origin, and not
the sample (or population) mean. Furthermore, testosterone levels
in untreated samples are expected to drop by approximately 50%
over the 3 d, suggesting that these differences must be taken into
account during data treatment and analysis. As a pragmatic solu-
tion to these difficulties we normalized testosterone measure-
ments in the following way, with only data used from the same
testis explants:
testosterone change=
sampletestosterone D0ð Þ − sampletestosterone D3ð Þ
controltestosterone D0ð Þ − controltestosterone D3ð Þ
[2]
Here sampletestosteroneðD0Þ and sampletestosteroneðD3Þ refer to the
treated measurements from the beginning (D0) and after 3 d
(D3). A testosterone change of 1 refers to no change in the testos-
terone production, and 0 to a complete suppression.
Statistical regression analysis was carried out by using a best
fit approach (Scholze et al. 2001) on the basis of two nonlinear
(sigmoidal) concentration–response functions (logit, Weibull),
with both considered as flexible enough to accurately describe
the experimental concentration–response data for the mixture
predictions. The best-fitting model of these two was then selected
for the mixture modeling. All regression analysis was performed
using Graphpad prism software (GraphPad Software, Inc., La
Jolla, California, USA).
Results
Selection and Effects of Chemicals Screened for Inclusion
in Mixtures
Candidate chemicals were selected for inclusion in our multi-
component mixtures if they met the following criteria: a) They
had to be able to suppress testosterone synthesis in the FEGA,
and b) they had to show dose–response curves with almost com-
plete inhibition of testosterone synthesis. Compliance with these
two criteria ensured that expected combination effects could be
calculated over a large range of responses on the basis of the
Figure 1. Concentration–response data for individual chemicals from the organotypic culture system in human fetal testes. (A,B) The graphs show the experi-
mental data as mean±SEM of at least three independent studies together with the regression curves (solid lines) and their respective 95% confidence intervals
(CI) (dashed lines). Testosterone production is represented as relative to the first day of culture (D0) production and the control level, see text for more details.
Gray areas indicate the cytotoxic concentration ranges, the vertical dashed line the concentrations expected to inhibit testosterone secretion in human fetal testis
by 50%.
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effects of the single mixture components. Furthermore, all
selected chemicals had to be of relevance to human exposures.
Because too few chemicals were known that fulfilled all these cri-
teria when we began our work, we engaged in a screening exer-
cise in which 27 chemicals from a wide range of use categories
and applications, and to which pregnant women might be
exposed, were tested (see Table S1). Of these 27 chemicals, 11
compounds qualified for inclusion in our mixtures (Table 1; see
also Figure S1). Not only did this effort provide detailed dose–
response data about many chemicals already known to be active
in the FEGA (Ben Maamar et al. 2015; Eladak et al. 2015;
Mazaud-Guittot et al. 2013; Pont et al. 1982), it also uncovered
several new chemicals whose capability of suppressing testoster-
one synthesis in humans was not previously recognized: the pes-
ticide imazalil, which had been described before as an androgen
receptor antagonist in the MDA-kb2 cell line (Orton et al. 2011);
the pesticides propiconazole and bitertanol, which had been pre-
viously shown to decrease the testosterone production in the
NCI-H295R cell line (Taxvig et al. 2013), and the fungicide pro-
chloraz and the selective estrogen receptor modulator clomifen,
both known to be anti-androgenic in the rat (Laier et al. 2006;
Fontenot et al. 2015). Theophylline, a caffeine metabolite and
pharmaceutical used in the treatment of asthma had previously
been shown to impair Leydig cell development in the rat (Pollard
et al. 2001). Our data also revealed anti-androgenic properties of
the teratogenic drug valproic acid and the pesticide chlordecone
(Figure 1A,B, Table 1).
Dose–Response Analysis of Individual Chemicals
For all 11 chemicals included in the mixture experiments, we
determined the best-fitting regression models by nonlinear regres-
sion analysis, together with the 95% confidence intervals of these
estimates (Figure 1A,B). The regression model parameters and
estimated levels associated with a 50% inhibitory response are
listed in Table 1. Judging by the concentrations required to
induce effects of this magnitude, the potencies of the 11 selected
chemicals differed approximately 500-fold. With 2:23× 10−7 M,
the pesticide prochloraz was the most potent of the tested chemi-
cals, and the drug theophylline the weakest (5:04× 10−5 M).
General Toxicity of Antiandrogens Tested
At levels equivalent to, or even exceeding, half-maximal suppres-
sions of testosterone synthesis by all of the 11 chemicals, the
Figure 1. (Continued.)
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Figure 2. Single compound histopathology of treated human fetal testes explants at the highest nontoxic concentrations after a culture of 96 h. (A,B)
Steroidogenic Leydig cells were labeled by immunostaining of CYP11A1 in cultured explants of gestational week (GW) 10–12. The 3,3 0-diaminobenzidine tet-
rahydrochloride staining appears brown in all photos, and sections were counterstained with hematoxylin. Testis cords and interstitial tissue could be easily
identified in all the sections (dashed lines represent testis cords). Bar = 20 lm.
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tissues appeared intact and well organized, with the expression of
CYP11A1 clearly visible (Figure 2A,B). We also monitored pos-
sible apoptotic effects by immunolabelling of cleaved caspase-3
positive cells. Our results showed that the tested chemicals did
not induce tissue toxicity at doses equal to, or even higher than,
those used in the mixture experiments described below (see
Figure S2).
Mixture Experiments
With the intention of analyzing whether combination effects could
be predicted accurately on the basis of the effects of its components,
we investigated four different mixtures composed of four and eight
components. A second aim was to assess the impact of co-
exposures on the dose–response curve of a specific chemical and to
assess how this varies with the number of mixture components. To
realize this aim, therehad to beone chemical common toall themix-
tures;we selectedBPA for this purpose, in view ofwidespread con-
cerns about its endocrine disrupting potential (Ben Maamar et al.
2015) and its ubiquity as an environmental pollutant.
In each case, we began by calculating the mixture dose–
response curves that were to be expected if all components acted
together according to the principles of dose addition. These cal-
culations relied on the best-fitting regression models for each
individual mixture component (Table 1, Figure 1A,B) and the
mixture ratios chosen for each mixture. The choice of mixture ra-
tio was driven by the need to ensure that each single chemical
contributed significantly to the overall combined effect of the
mixture. Mixture ratios were set to reflect the potencies of
all mixture components in the FEGA (Table 1). We then pre-
dicted the expected combination effects together with their 95%
bootstrap confidence intervals. These predictions defined the
boundaries of the dose ranges that were examined in the mixture
experiments (Figure 3).
As the screening process of the selected compounds was pro-
gressing, we began by testing two four-component mixtures that,
apart from BPA, contained pharmaceutical drugs. Mixture I com-
prised the antifungal ketoconazole, the selective estrogen receptor
modulator clomiphene, the anticonvulsant valproic acid, and BPA.
Inmixture II, clomiphenewas replacedwith theophylline, a metab-
olite of caffeine,which is used in the therapyof asthma andother re-
spiratory diseases. Thus,mixture IIwas composed of ketoconazole,
BPA, valproic acid, and theophylline. Both mixtures I and II
showed a clear dose–response pattern for declining testosterone
levels (Figure 3). Even at mixture doses associated with 80% sup-
pression of testosterone levels therewere no signs of impairment of
histopathology or of cleaved caspase-3 immunostaining, demon-
strating that confounding toxicity did not influence the observed
anti-androgenic effects of the mixture (Figure 4). In both cases, the
experimentally observed effects stayed well within the statistical
95% confidence belt of the additivity prediction curves, which led
us to conclude that the mixture effect was additive (Table 2,
Figure 3).
These observations motivated us to extend our studies to assess
whether additivity can be considered as the default assumption for
the joint actionof compounds ondisrupting testosteroneproduction
in the human male fetus. This required investigations of mixtures
that contained a larger number of components and apart from drugs
also included other chemicals. Accordingly, we composed mixture
III by adding theophylline,BPS, and the pesticides chlordecone and
imazalil to the ingredients of mixture I.Mixture IV contained BPA,
theophylline, BPS, and the pesticides chlordecone, imazalil, biter-
tanol, prochloraz, and propiconazole (Table 1). As seen previously
with the four-component mixtures, the experimentally observed
Figure 3. Predicted and observed testosterone secretion in human fetal testis by four chemical mixtures. Experimental data are shown as mean±SEM (blue) of
at least four independent experiments. Testosterone production is represented as relative to the first day of culture (D0) production and the control level, see
text for more details. The mixture effects were predicted according to dose addition (DA) (thick red curve), with dashed curves the respective 95% confidence
intervals (CIs) (dotted orange lines).
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suppressions of testosterone synthesis of both these eight-
componentmixtures fellwithin the 95%confidence belts of the pre-
diction curves and agreed well with the expectation that the com-
bined effects of these agents are additive. Thus, the predictability of
mixture effects did not diminish as we increased both number and
variety of mixture components (Table 2, Figure 3). As before with
the four-component mixtures, there was no evidence of confound-
ing toxicitywith either of the eight-componentmixtures (Figure 4).
The Impact of Co-Exposures on the Apparent Potency of
Anti-Androgenic Chemicals
Finally, we investigated the magnitude of errors that might be
introduced by a disregard of co-exposures to similarly acting
chemicals during the process of hazard characterizations. We
approached this by adopting the perspective of a risk assessor
attempting to define safe exposures for a specific chemical in iso-
lation, when in reality there is co-exposure to several other chem-
icals. To this end, we compared the dose–response curves of all
the single components of mixture III tested on their own (right-
hand curves in Figure 5A) with those obtained in the presence of
the other seven mixture constituents (left-hand curves in Figure
5A). These latter curves were constructed by plotting each chemi-
cal’s dose in the mixture against the observed mixture effects. In
all cases, the curves shifted to the left, towards lower concentra-
tions, indicating increased potency relative to the single chemical,
but the extent of these shift depended on the chemical considered
in these analyses. Potencies (judged on the basis of the concentra-
tions required to achieve half-maximal effects) increased by a
factor of 10 (imazalil) and up to a factor of 10,000 (theophylline)
due to co-exposure to the seven other chemicals in the mixture.
Because BPA was present in all four mixtures, this offered
the opportunity of investigating how these potency shifts are
influenced by the number of chemicals in the mixtures. As shown
in Figure 5B, the apparent potency of BPA increased by a factor
of about 3 in the presence of three compounds, and by a factor of
10 in the presence of seven compounds. A BPA level judged to
be without effect on its own (1× 10−6M) produced a 75% sup-
pression of testosterone synthesis in the presence of the seven
other chemicals that made up mixture III.
For mixture III, we also compared the concentrations of each
component that produced a 20% testosterone suppression (EC20)
with the concentrations present in a mixture causing a 50% effect.
As shown in Table 3, the concentrations of every chemical in the
mixture were by a factor of 2–3 lower than their EC20. This sug-
gests that in combination, the components of this mixture are
able to work together at levels that had they been given singly
would not have produced observable effects.
Discussion
Concerns that the traditional focus of chemical risk assessment
on single chemical exposures might underestimate the risks asso-
ciated with adverse effects of multiple chemicals have been
expressed earlier (Kortenkamp 2014), but the impact on risk esti-
mates has been proven difficult to define. This is partly due to
incomplete information about the complexity of combined human
exposures and to a lack of clarity about the approaches and meth-
ods that should be used for mixture risk assessment. Our study
provides important advances in improving the scientific basis for
human mixture risk assessment. To our knowledge, we demon-
strate for the first time that the mixture assessment concept of
dose addition is applicable to human tissues. This not only
enabled us to avoid certain uncertainties associated with animal-
to-human extrapolations, but also enabled us to use a predictive
approach. Rather than studying every conceivable combination
of chemicals within a mixture, the joint effects of anti-androgenic
chemicals in the FEGA can now be approximated on the basis of
the effects of each single component by using dose addition as
the default assumption.
To utilize the FEGA in multi-component mixture studies
required making a leap from qualitative studies to quantitative
dose–response analyses. Due to the inhomogeneity of the mate-
rial and the variations inevitably introduced through the age
Table 2. Statistical uncertainty of predicted and observed effect concentrations for mixtures [effect concentration EC50 (M)].
Observed Predicted
Mean 95% CI Mean 95% CI
Mixture I 2:95× 10−6 2:35× 10−6, 3:96× 10−6 2:94× 10−6 1:32× 10−6, 4:53× 10−6
Mixture II 1:81× 10−6 1:27× 10−6, 2:40× 10−6 2:96× 10−6 1:01× 10−6, 4:79× 10−6
Mixture III 5:62× 10−6 3:62× 10−6, 8:99× 10−6 9:40× 10−6 5:74× 10−6, 1:17× 10−5
Mixture IV 8:35× 10−6 5:47× 10−6, 1:32× 10−5 1:13× 10−5 8:19× 10−6, 1:46× 10−5
Note: Concentration-additivity predictions are based on regression fits to experimental data (Table 1, Figure 3). CI values denote the upper and lower limits of the 95% bootstrap inter-
val of the effect concentration. CI, confidence interval.
Figure 4. Histopathology of explants at high-effect concentrations of the
mixtures. Steroidogenic Leydig cells and apoptotic cells were labeled in cul-
tured explants of GW 10–12 human fetal testis with an immunostaining of
CYP11A1 (left panel) and an anticleaved caspase-3 antibody (right panel),
respectively. The 3,3 0-diaminobenzidine tetrahydrochloride staining appears
brown, and sections were counterstained with hematoxylin. Testis cords are
highlighted by dashed lines, and the Leydig cells within the interstitial tissue
can be identified by their brown labeling. Bar = 20 lm.
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Figure 5. The impact of co-exposures on the dose–response curves of individual mixture components. A) The concentration–response curves on the right in
each panel show the responses for each compound tested on its own, and the curves on the left, the response if tested in combination with seven other com-
pounds in mixture III (red solid lines). Testosterone production is represented as relative to the D0 production and the control level, see text for more details.
B) The shift in the concentration–response curve of BPA in the presence of mixtures I–IV. C) Comparison of the concentrations of BPA associated with 50%
testosterone synthesis suppression in the presence of mixtures I–IV.
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differences of the fetal testes, the assay outcome (fetal testoster-
one production) shows high variability, which we had to deal
with by rigorously controlling experimental conditions. We
achieved good reproducibility, which was essential for realizing
our goal of analyzing whether the combined effects of multiple
chemicals can be predicted accurately on the basis of the effects
of individual mixture components and of assessing the impact of
co-exposures on the dose–response curves of single chemicals.
A difficulty in using the FEGA as a screening method for the
identification of chemicals with endocrine disruptive properties is
the limited availability of human fetal tissue. An additional chal-
lenge is in the requirement of collecting tissues of comparable
age.
Our study provides direct evidence that co-exposures should
be considered when evaluating the risk of a single chemical. We
show that effects of a single chemical are underestimated when
co-exposure to related chemicals are not considered, and that this
underestimation is driven by the number, type, and potency of
co-occurring chemicals. In this study, overlooking co-exposures
to only seven chemicals led to an underestimation of the potency
of BPA by a factor of 10. A corollary of the principles of dose
addition is that co-exposure to a larger number of chemicals will
drive up the extent of such underestimations if these chemicals
are present at levels equipotent with the components we used in
our experiments. Alternatively, replacement of some components
with larger numbers of other chemicals, but at lower levels, may
lead to similar underestimations. More studies using the FEGA
are needed to establish these assumptions.
Based on our findings, we suggest that the impact of mixture
effects on male sexual differentiation during the first trimester of
pregnancy may be considerable. However, although in this study
the selection of chemicals was empirically based on the results
obtained in our dose–response study, analysis of individual
chemicals, assessment of the extent of adverse effects in human
fetuses will require more knowledge about the spectrum of chem-
icals capable of suppressing testosterone synthesis. Future FEGA
studies will help close this knowledge gap, especially if based on
companion studies that identify all of the exogenous chemicals
found in maternal and fetal tissues.
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